Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01489813 · ClinicalTrials.gov registry record · Phase 2
Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT01489813 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 36 participants.
The verdict
NCT01489813, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
Patients with non-invasive bladder cancer are often treated with intravesical therapy in order to prevent the recurrence of bladder cancer. Intravesical therapy can cause many lower urinary tract symptoms, which can limit the dose of therapy and therefore efficacy of treatment. There have been a number of studies that suggest a chemical found in soy beans may be able to help with these side effects. This chemical is called genistein and can be extracted and given to study subjects in pill form. In this study, the investigators would like to have patients placed into two different groups. One group would take genistein and the other group would take a placebo, a sugar pill that looks like the genistein pill. In doing this study the investigators hope to explore the findings from other studies to see if lower urinary tract symptoms are reduced and to see if recurrence rates for patients are affected by genistein. The study would take about four and a half months total.
Interventions
- DRUG Sugar pill
- DRUG Genistein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-05-19 |
| Est. Completion | 2024-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01489813
The ClinicalTrials.gov registry entry for NCT01489813 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sugar pill is the first listed.
NCT01489813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01489813 about?
NCT01489813 is a clinical study titled "Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment". Patients with non-invasive bladder cancer are often treated with intravesical therapy in order to prevent the recurrence of bladder cancer. Intravesical therapy can cause many lower urinary tract symptoms, which can limit the dose of therapy and therefore efficacy of treatment. There have been a num...
What is the current status of trial NCT01489813?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2017-05-19. Estimated completion is 2024-08-31.
What interventions are being tested in trial NCT01489813?
The interventions under investigation include: Sugar pill (DRUG), Genistein (DRUG).
Who is sponsoring clinical trial NCT01489813?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.